Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Earnings

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

By The Northwire Desk — AI Analysis Mar 27, 2026 · 08:10 QNTM · 5.37 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma reported Q4 2025 and full‑year 2025 audited financial results, showing a cash position of $11.3 M (including digital assets) and reduced operating expenses to $15.3 M.
  • Positive clinical milestones were disclosed: Phase 1 oral toxicity studies for MS drug candidate Lucid‑21‑302 completed with no safety signals; IND filing planned for H1 2026; first MS patient scanned in a PET imaging study with MGH.
  • The company launched a Regulation D 506(c) private placement to raise up to $5 M for growth and potential IPO of its unbuzzd™ brand, and announced a Health Canada product licence for Qlarity.

Key Details

  • Financial Position: Cash & digital assets = $11.3 M USD; sufficient working capital projected through Jan 2028.
  • Operating Expenses: FY 2025 total $15.3 M, down ~5% YoY from $16.1 M (2024).
  • Trade Payables: Reduced ~50% to $2.0 M (from $4.1 M) as of 31‑Dec‑2025.
  • R&D Fees: Decreased to $2.8 M from $6.1 M YoY, reflecting completion of Phase 1 trials and tax credits.
  • G&A Expenses: Down to $9.0 M from $9.4 M YoY.

Clinical / Pipeline Updates

  • Lucid‑21‑302 (MS program):
  • Completed 3‑month & 6‑month oral toxicity studies – no toxicity or significant side effects observed.
  • Oral formulation selected for Phase 2; contract manufacturing agreement signed with leading CDMO.
  • First MS patient scanned in joint PET imaging study with Massachusetts General Hospital to validate myelin integrity monitoring.
  • Stability studies completed; IND filing targeted H1 2026.
  • Principal investigator identified; CRO negotiations advanced for Phase 2 trial.

  • Preclinical efficacy study initiated in heart‑failure model.

  • unbuzzd™ (dietary supplement):

  • Peer‑reviewed publication (Zenodo) shows accelerated BAC reduction and reduced intoxication/hangover symptoms in double‑blind crossover trial (NCT06505239).
  • Health Canada granted Product Licence (PN 80144141) for Qlarity (energy & metabolism product); licence also permits Canadian sale of unbuzzd™.
  • Unbuzzd Wellness Inc. licensed U.S. rights; company hired MNP as auditors in preparation for potential IPO.

Financing / Capital Raising

  • Regulation D 506(c) Offering: Launched to raise up to $5 M USD to fund unbuzzd™ growth, distribution, and a prospective go‑public transaction.
  • All warrants held by hedge funds expired in 2025.

Legal Update

  • Quantum filed a memorandum of law opposing CIBC World Markets and RBC Dominion Securities’ joint motion to dismiss the lawsuit alleging stock‑market manipulation; case pending in U.S. Southern District of New York.

Corporate Governance

  • Board Change: Effective 27 Mar 2026, Terry Lynch resigned from the board for time‑constraint reasons.

Notable Quotes

“We are in a significantly stronger cash position…operationally we continue to strengthen our balance sheet and expand our reach in the capital markets to execute on upcoming milestones.” – Donal Carroll, CFO

“We made significant progress with our MS program…Lucid‑MS has completed toxicology studies and we are optimistic about its potential to protect myelin in MS patients.” – Donal Carroll, CFO

Materiality Assessment: Material – Positive (financial results, clinical milestones, financing activity, and legal update constitute material information for investors).

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other